93 results about "Astragaloside IV" patented technology

The present invention discloses a method for preparing astragalus methylglucoside by utilizing enzymatic hydrolysis of astragalus saponin glycosyl. It is characterized by that it uses an enzyme method to hydrolyze astragalus saponin glycosyl to prepare astragalus methylglucoside. The described enzyme is prepared by using astragalus saponin or flavone or isoflavone as fermentation enzyme-producing inductor and utilizing bacteria, streptomycete, mold, saccharomycetes and basidiomycetes to make fermentation. Said invention can be used for preparing astragalus tablet and powder products with high astragalus methylglucoside content.

The invention relates to a method for extracting astragaloside IV from astragalus and belongs to the technical field of medicines. From an economic prospective, the convention method greatly increases production cost and period, which is unfavorable for the competition of enterprises on market. The method provided by the invention comprises the following steps: a, soaking an astragalus medicinal material in alcohol, heating, extracting and concentrating the extract to a certain volume; b, adding alcohol into the concentrate; c, adding petroleum ether, normal hexane or ethyl acetate into the solution obtained by the step b for extraction, and collecting a bottom phase; d, concentrating the lower phase till the lower phase contains no ethanol, adding alkaline solution and dehydrating for 0.5 to 10 hours at 30 to 100 DEG C; and e, adding n-butyl alcohol and one or several of ethyl acetate, normal hexane or petroleum ether for mixed extraction, collecting an upper phase, washing the upper phase, evaporating the upper phase to dryness, and crystallizing to obtain astragaloside IV. The purity of the astragaloside IV prepared by the method can reach 90 to 99 percent.

The invention relates to a detection method of a Chinese preparation mixture for invigorating the spleen and replenishing qi. The Chinese preparation mixture comprises the following ingredients: 280 g of astragalus, 84 g of Codonopsis pilosula, 140 g of liquorice, 84 g of rhizoma atractylodis macrocephalae, 84 g of Chinese Angelica, 84 g of cimicifugae foetidae, 84 g of radix bupleuri, 84 g of tangerine peel, 28 g of ginger, and 56 g of Chinese date. The detection method comprises the following steps: identifying the liquorice, Chinese Angelica and tangerine peel in the mixture, and determining the content of Astragaloside IV in the mixture.

The invention discloses a culture medium capable of promoting the division growth of mesenchymal stem cells, which comprises a serum-free basic culture medium and an additive added on the basis of theserum-free basic culture medium, wherein the additive comprises a hibiscus mutabilis extract, seaweed polysaccharide, astragaloside IV, human serum albumin, transferrin, glutamine, platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and vitamin A; the hibiscus mutabilis extract has antioxidant and cell activating activity, and can effectively promote the growth of cell metabolic by compounding seaweed polysaccharide and astragaloside IV; human serum albumin, transferrin, glutamine and vitamin A provide essential nutrient substances for the growth of stem cells; platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and other cytokines together promote the rapid growth and proliferation ofstem cells; the culture medium not only can improve the growth activity of mesenchymal stem cells, shorten the culture time, promote the expression of cell growth factors, but also can maintain the stem cell activity of the differentiation potential of mesenchymal stem cells; stem cells are not differentiated in daily culture, thereby providing convenience for scientific research.

The invention relates to a method of measuring an effective component in a traditional Chinese medicine, and particularly relates to a method of measuring the content of astragaloside in heart-tonifying pulse-restoring granules. The method includes a step of preparing a reference substance solution, namely a step of measuring a proper amount of an astragaloside reference substance and adding water-containing methanol or a mobile phase to prepare into a solution containing 0.16-0.24 mg1/mL of astragaloside; a step of preparing a sample solution to be measured, namely a step of weighting the heart-tonifying pulse-restoring granules, extracting with an alkali water solution having a concentration of 2-5%, adding the extract liquid into a solid phase extraction column, and eluting with methanol, and a step of measuring, namely a step of separately injecting 5-20 muL of the reference substance solution and the sample solution to be measured into a high performance liquid chromatograph.

The invention discloses a method for determining the content of Astragaloside IV in a traditional Chinese medicinal composition. The method concretely comprises the steps of preparing a tested substance solution, preparing a reference substance solution and determining. The determination method is helpful for controlling the quality of medicines, and improves the safety and the reliability of the medicines.

The invention provides a method for analyzing all components of an angelica sinensis six-yellow decoction, and belongs to the technical field of pharmaceutical analysis. An ultra-high performance liquid chromatography tandem quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) technology is adopted to detect an angelica sinensis six-yellow decoction sample, and 15 chemical reference substances are adopted at the same time: baicalin, wogonoside, berberine hydrochloride, epiberberine hydrochloride, coptisine hydrochloride, palmatine hydrochloride, phellodendrine hydrochloride, astragaloside, calycosin-7-glucoside, ferulic acid, chlorogenic acid, ligustilide, verbascoside, baicalein and wogonin are adopted to confirm a detection result of the angelica sinensis six-yellow decoction andclearly identify 68 components; comprehensive analysis of the components of the angelica sinensis six-yellow decoction is realized, and the reliability of quality control is improved.

The invention relates to application of astragaloside IV in the preparation of drugs for treating and delaying intervertebral disc degeneration. Astragaloside IV serving as a plant extract with good biological activity has the advantages that the drug dosage is low and the anti-apoptotic effect on nucleus pulposus cells is obvious; compared with Western medicine, astragaloside IV serving as traditional Chinese medicine is mild in anti-apoptotic effect, and an alternative treatment drug can be provided for the comprehensive treatment of intervertebral disc degeneration diseases.

The invention belongs to the field of traditional Chinese medicine preparations, and particularly relates to a preparation method of a venation-dredging preparation. The preparation method improves the content of three kinds of iconic medicinal components of chlorogenic acid, astragaloside IV and berberine hydrochloride in the venation-dredging preparation, the extraction amount of Chinese angelica and rhizoma atractylodis volatile oil is improved, and the clinical efficacy of the product is ensured; at the same time, the three kinds of precious animal medicinal materials of leeches, centipedes and scorpion are extracted by a double extraction method of alcohol-refluxing and water-adding decoction, which can ensure the comprehensive and full extraction of water-soluble and alcohol-solublecomponents in animal medicinal materials, the preparation reduces the content of ineffective impurities in the preparation, reduces the dosage, improves the taste, and improves the compliance of patient administration.

The invention relates to the field of medicament extraction and refining, which is a process for extracting astragaloside IV and solves the problems that the products of the prior art has low yield or needs special devices and technology, is not beneficial to generalization and production and the like. The invention provides a simple, effective, high-yield and new extracting process capable of realizing the industrial large-scale production. The process is operated by the following steps of: cutting raw materials in to pieces or coarse grains, adding enzyme for enzymolysis, and after the enzymolysis, extracting the raw materials by water; extracting and refilling the astragaloside IV. The invention combines the enzymolysis method with a water extraction method and an ethanol extraction method, such that the astragaloside IV in the raw materials can be extracted in maximum; the waste of the raw materials is avoided, the production rate of the astragaloside IV is improved, and the yieldof the astragaloside IV is high. In addition, a solution mixing butyl acetate and tert-butyle alcohol is used for refilling, such that the finally obtained product has good quality, stable formation and high yield; and the raw materials are repeatedly and fully utilized in the whole production process, thus the economic efficiency is improved, the environment is protected, and the invention is suitable for the industrial production.

The invention relates to a Qitian drop pill extract, a Qitian drop pill and a production method thereof. The Qitian drop pill extract comprises the following ingredients: astragalus hoangtchy, radices paeoniae rubra, integripetal rhodiola herb and safflower. The Qitian drop pill consists of the Qitian drop pill extract and a pharmaceutical base. The Qitian drop pill extract comprises improved quantities of hydroxysafflor yellow, peoniflorin, integripetal rhodiola herb and astragaloside IV, and the production method of the Qitian drop pill extract is simple. Pharmacodynamic studies of the Qitian drop pill prove that the Qitian drop pill of different dosage teams has different degrees of protective functions to rat myocardial ischemia injury, and the curative effects of the dosage teams of Qitian drop pill is similar with that of Compound Danshen Drop Pill. The production method of the Qitian drop pill is simple.

The invention relates to a method for detecting astragalus-chickpea particles. Raw materials of the astragalus-chickpea particles mainly comprise astragalus, red-rooted salvia root, sealwort, chickpea, cicada shell and lactose. The detection method comprises content measurement: measuring the content of astragalus and red-rooted salvia root in the particles with a high performance liquid chromatography method, wherein every bag of astragalus-chickpea particles contains not less than 35.0 mg of red-rooted salvia root counted by danshinolic acid BC36H30016 and not less than 1.0 mg of astragalus counted by astragaloside A C41H68014. The detection method can further comprise thin layer chromatography, character detection and particle detection. By establishing a detection method with high accuracy, high repeatability and high stability, the weight of the astragalus-chickpea particles can be controlled effectively, and the quality of the astragalus-chickpea particles is stable, controllable, efficient and safe.

The invention discloses a novel traditional Chinese medicine for treating hypoleucocytosis caused by radiotherapy and chemotherapy for treating cancers and a preparation method thereof, and also discloses pharmacological effects and clinical application of the novel traditional Chinese medicine. The novel traditional Chinese medicine provided by the invention comprises pearl ginseng and astragalus mongholicus. The preparation method of the novel traditional Chinese medicine comprises the following steps of adding water into pearl ginseng and astragalus mongholicus, respectively carrying out decoction extraction, merging the extract, carrying out concentration, carrying out alcohol precipitation, standing, recovering ethanol of supernate, carrying out condensation, and mixing the concentrated solution and one or more pharmaceutically acceptable carriers/auxiliary materials to obtain an oral solution, wherein the oral solution is the novel traditional Chinese medicine. The oral solution named as a pearl ginseng-astragalus mongholicus oral solution has active components of total saponins and plant polysaccharides, wherein the total saponins comprise ginsenoside Ro, panax japonicus saponin IVa and astragaloside IV. The oral solution can be utilized for treating diseases of hypoleucocytosis, lusterless complexion, mental and physical fatigue, palpitaition, shortness of breath, insomnia, dry throat and inappetence after radiotherapy and chemotherapy for treating cancers.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which comprises astragalus root saponin extract 35.0-75%, red sage root extract 15.0-55.0%, panaxtriol saponins extract 2.5-15.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in panaxtriol saponins extract is 80-90%, the content of total saponins in astragalus root saponin extract is 70-98%, the content of Astragaloside IV is 5-15%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of red sage root or panaxtriol saponins, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, which comprises astragalus root saponin extract 35.0-75%, red sage root extract 15.0-55.0%, pseudo-ginseng saponin extract 2.5-15.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in pseudo-ginseng saponin extract is 70-98%, the content of total saponins in astragalus root saponin extract is 70-98%, the content of Astragaloside IV is 5-15%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of red sage root or notoginseng saponin, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention relates to a method for preparing cycloastragenol through microorganism mixed fermentation, transformation and degradation of astragaloside iv. Two strains of fusarium proliferatum 0821(CGMCC NO.16482 ) and Fusarium verticillioides 0213 (CGMCC NO.16481 ) which are screened out are used, the astragaloside iv is used as a substrate, and through mixed fermentation of the two strains, the cycloastragenol is prepared. A technique for mixed fermentation with two microorganisms is adopted to degrade the astragaloside iv so as to obtain the cycloastragenol high in purity. The technological flow is simple, the cost is low, and the entire technological process is performed at normal temperature and normal pressure. The required equipment condition is low, the method is suitable for mass production, the conversion rate of the final cycloastragenol is as high as 80% or above, and the purity is as high as 95% or above.

The invention provides a method for detecting Chinese medicinal capsules for treating breast disease, such as capsules for treating nodule in breast by dissolving stasis. The detection method comprises: 1, detecting active ingredients from Chinese angelica by thin-layer chromatography; 2, detecting astragaloside IV and icariin by thin-layer chromatography; 3, detecting saikoside alpha by thin-layer chromatography; and/or 4 detecting active ingredients from Chinese pyrola herb by thin-layer chromatography. The detection method can accurately and completely reflect the content of medicinal components of the capsules for treating nodule in breast by dissolving stasis and therefore can provide a guarantee for the industrial production and clinic use of the capsules for treating nodule in breast by dissolving stasis.

The present invention establishes a simultaneous quantification method for mouse plasma based on UPLC-HRMS, in which the method targets astragaloside IV and cycloxanthine that is the main metabolite of astragaloside IV. The quantitative time of the method is 3 mins, digoxin is used as an internal standard, and only 20 [mu]L of mouse plasma is needed, thus having the advantages of rapidity, high sensitivity and strong specificity. After being precipitated by the protein, the sample is filtered by dephospholipidation plate, which effectively reduces the matrix effect of endogenous metabolites ofphospholipids in plasma on the analyte. Ultra-high performance C18 column is used as the analytical column to detect two kinds of analytes and internal standards in the electrospray ion source positive ion selective ion monitoring mode. The linear range of the two analytes is 1-200ng/mL, the intra-day and inter-day precision is <=8.6%, and the precision is <=8.8%, which indicates that the methodhas good precision and accuracy. The method for simultaneously quantitatively detecting astragaloside-IV and cycloxanthine in mouse plasma was successfully applied to the pharmacokinetic study of astragaloside IV mice.

The invention discloses a quality control method of Xuhanting medicament, which emends the quality control standard of the original Xuhanting granule and increases the content determination of astragaloside IV. The quality control method of Xuhanting preparation of the invention doesn't have disturbance in the negative comparison, has stronger exclusivity and better repeatability, is advantageous to realize effective controlling of the quality of Xuhanting preparation finished product, and insures the security and the efficiency of human body. The invention can be applicable to not only the quality control of Xuhanting granule but also the quality control of other prescriptions such as Xuhanting capsule, oral liquid, and the like.